(IN BRIEF) Roche reported that its phase III MAJESTY trial met its primary endpoint, showing that treatment with Gazyva/Gazyvaro enabled significantly more patients with primary membranous nephropathy to achieve complete remission at two years compared with tacrolimus. The study also … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Security & Safety, Switzerland, Technology
Tagged anti-CD20 monoclonal antibody, autoimmune kidney disease, B cell depletion therapy, clinical trial phase III, European Medicines Agency, FDA, Gazyva, Gazyvaro, idiopathic nephrotic syndrome, immunology pipeline, kidney function preservation, lupus nephritis, MAJESTY study, MAJESTY Trial Success Positions Gazyva for Possible First Approval in Primary Membranous Nephropathy Treatment, obinutuzumab, primary membranous nephropathy, remission outcomes, renal disease research, Roche, systemic lupus erythematosus
(IN BRIEF) Boehringer Ingelheim has entered into a multi-year collaboration with Cue Biopharma to develop and commercialize CUE-501, a first-in-class bispecific compound designed to selectively deplete harmful B cells in autoimmune diseases. The innovative therapy uses Cue’s Immuno-STAT™ platform to … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged autoimmune diseases, B cell depletion, biologics innovation, biopharma collaboration, bispecific compound, Boehringer Ingelheim, Carine Boustany, chronic disease treatment, Cue Biopharma, CUE-501, Daniel Passeri, drug development, Immuno-STAT, Immuno-STAT platform, immunology pipeline, inflammatory diseases, licensing agreement, memory T cells, milestone payments, partnership, precision medicine, royalty payments, strategic partnership, T cell engagers, targeted biologics, up-front payment
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?